Delivery Order SPE2DB22D1202-SPE2DB25FVGT5
Award Date 8/7/25
Potential Completion Date 8/8/25
Potential Value $2.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, non-set-aside contract with a completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, reflecting the Defense Logistics Agency's procurement of...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on July 31, 2025, with completion scheduled for August 1, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine used for immunization of adults. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award...
- The Defense Logistics Agency awarded a $4,212.40 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 31, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of infection caused by...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B vaccine (20 mcg/0.5 mL syringe) on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $4,623.24 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 23, 2025, with an ultimate completion date of July 24, 2025. HEPLISAV-B is a hepatitis B vaccine indicated for adult immunization. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $2,106.20 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 and older, and this...
- The Defense Logistics Agency awarded a delivery order valued at $8,424.80 to AmerisourceBergen Drug Corp on August 4, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded. HEPLISAV-B is a recombinant hepatitis B vaccine commonly procured by...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $4,279.18. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult...
- The Defense Logistics Agency awarded a delivery order valued at $15,164.64 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with an ultimate completion date of July 23, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly...